Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
Acute Leukemia
Explore 60 assets in Acute Leukemia →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03970096CT.gov Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | — | Recruiting | — | — | — |
NCT01660607CT.gov Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive (this asset) | Fred Hutchinson Cancer Center | P2 | B · 58 |
| Fludarabine | Sawa Ito, MD | P2/3 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Cytarabine | Janssen Research & Development, LLC | P2/3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Methotrexate | SWOG Cancer Research Network | P3 | BB |
| Rituximab | SWOG Cancer Research Network | P2 | BB |
| Adriamycin | SWOG Cancer Research Network | P2/3 | BB |
| Prednisone | SWOG Cancer Research Network | P2 | BB |
+42 more in the Acute Leukemia cohort
Other indications for Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P2/3 | BBB · 74 |
| Graft Versus Host Disease | — | P2/3 | BB · 67 |
| Myelodysplastic Syndrome | — | P2/3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive in Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/peripheral-blood-stem-cells-allogeneic-cd34-positive-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →